● Recruiting

A Phase 2 Study of the Safety and Efficacy of Brepocitinib in Adults With Cutaneous Sarcoidosis (BEACON)

Condition: Cutaneous Sarcoidosis · Sponsor: Priovant Therapeutics, Inc.

PhasePhase 2

Planned participants28

Who can joinAll sexes, 18 Years to 75 Years

Healthy volunteersNo

About this study

This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with cutaneous sarcoidosis.

This description comes directly from the study's public registry record.

Talk to the study team

Clinical Trial Administrator · (212) 634-9743 · clinicaltrials@priovant.com

Always discuss trial participation with your own doctor first.

Locations (4)

Clinical Trial Site	San Francisco, California, United States	Recruiting
Clinical Trial Site	Durham, North Carolina, United States	Recruiting
Clinical Trial Site	Philadelphia, Pennsylvania, United States	Recruiting
Clinical Trial Site	Madison, Wisconsin, United States	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06978725